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Abstract
Background: In this study, we have evaluated the immunological status of hepatitis C virus (HCV)-infected patients
aiming at identifying putative biomarkers associated with distinct degrees of liver fibrosis. Peripheral blood and
tissue T-cells as well as cytokine levels were quantified by flow cytometry.
Results: Data analysis demonstrated higher frequency of circulating CD8+ T-cells and Tregs along with a mixed
proinflammatory/IL-10-modulated cytokine pattern in HCV patients. Patients with severe liver fibrosis presented
lower frequency of circulating CD8+ T-cells, higher levels of proinflammatory cytokines, but lower levels of IL-10,
in addition to the higher viral load. Despite the lower frequency of intrahepatic T-cells and scarce frequency of Tregs,
patients with severe liver fibrosis showed higher levels of proinflammatory cytokines (TNF and IFN-γ). The tissue
proinflammatory cytokine pattern supported further studies of serum cytokines as relevant biomarkers associated
with different liver fibrosis scores. Serum cytokine signature showed that mild liver fibrosis is associated with
higher IL-10 serum levels as compared to severe liver disease. There was a clear positive connection of IL-10 with
the TNF node in patients with mild liver fibrosis, whereas there is an evident inverse correlation between IL-10
with all other cytokine nodes.
Conclusions: These results suggest the absence of modulatory events in patients with severe liver damage as
opposed to mild fibrosis. Machine-learning data mining pointed out TNF and IL-10 as major attributes to differentiate
HCV patients from non-infected individuals with highest performance. In conclusion, our findings demonstrated that
HCV infection triggers a local and systemic cytokine ensemble orchestrated by TNF and tuned by IL-10 in such a
manner that mirrors the liver fibrosis score, which highly suggests the relevance of these set of biomarkers for clinical
investigations.
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Background
Hepatitis C vírus (HCV) infects 130–170 million people
worldwide, representing a global health problem [1–3].
Approximately 12–25 % of infected patients clear the
virus spontaneously. However, the majority of HCV-
infected patients remains infected and may evolve to the
chronic phase of the disease, characterizing a silent epi-
demic [4]. The major complications of HCV infection
are the progression to fibrosis, cirrhosis and hepatocellu-
lar carcinoma. These complications are related to high
rates of morbidity and mortality [5, 6].
The immune response in the HCV infection is respon-
sible for partial viral elimination and protective immun-
ity, but may also contribute to the liver damage [7].
HCV-induced liver damage is related to the robust tissue
inflammation and hepatocytes destruction, which may
result in progression to fibrosis. It has already been
described that these factors are closely associated with
cytokine production [8]. Cytokines are secreted upon
HCV-mediated activation of immune cells and exhibit es-
sential pleiotropical and adaptable functions in the im-
mune response during the course of infection and liver
damage [9]. Studies have shown that in chronic HCV in-
fection there is a correlation between the production of
proinflammatory cytokines, such as IFN-γ and TNF-α,
and progressive liver injury, while the regulatory cytokines
such as IL-4 and IL-10 may modulate the proinflamma-
tory immune response induced by the virus, allowing for
the establishment of a milder disease outcome [10]. The
liver fibrosis has important implications for the prognosis
of disease and for the decision-making on the onset of
therapeutic approaches. The information about the state
of fibrosis not only indicate response to treatment but also
reflects and suggests the development of major complica-
tions such as liver cirrhosis [11, 12]. As of now, there is no
clear knowledge of the relationship between the local and
systemic production of cytokines and the participation of
immune cells in liver fibrosis. Considering the lack of
information on the local and systemic immunological
biomarkers that correlate with the progression to liver
fibrosis, this study aimed at investigating the balance
between inflammatory and regulatory events in the per-




This study was approved by the Ethics Committee at the
Tropical Medicine Foundation “Dr. Heitor Vieira Dour-
ado” (Protocol#CEP:2339) and are in accordance with
the Resolution 466/12 from the Brazilian Ministry of
Healthy and also with the Helsinki Declaration of 1975.
Signed informed consent was obtained from each par-
ticipant for the use of biological materials and publica-
tion of data.
This study included 46 subjects living in Manaus,
Amazonas, Brazil. Subjects were categorized into two
subgroups referred as: Hepatitis C Virus-infected pa-
tients (HCV) infected patients and Non-infected patients
(NI). HCV group comprised 18 untreated patients from
both genders (10 males and 8 females), with age ranging
from 26 and 66 years (50 ± 8.9) contacted at the Tropical
Medicine Foundation Dr. Heitor Vieira Dourado (FMT-
HVD), with positive serologic test for HCV infection
(anti-HCV IgG detected by ELISA). Patients co-infected
with hepatitis A, B, D, E, human immunodeficiency virus
(HIV) and those who had started treatment for HCV in-
fection or presented decompensated cirrhosis (Child-
Pugh B or C) were excluded from the study. HCV pa-
tients were further sub-categorized into two subgroups
referred as F1-2 (n = 11) and F3-4 (n = 7) to according
the METAVIR score for liver fibrosis (Table 1).
The control group was composed of 28 healthy subjects
from both genders (20 males and 8 females), with age ran-
ging from 25 and 58 years (40.3 ± 9.1) (Table 1), recruited
as blood donor candidates at “Hospital Foundation of
Hematology and Hemotherapy of Amazon (FHEMOAM)
with negative results for serologic screening tests, includ-
ing viral hepatitis (A, B and C), HIV, syphilis, Chagas dis-
ease and HTLV-1/2.
Biological samples
Five milliliters of whole blood were collected in EDTA
tubes from each patient to perform the phenotypic ana-
lysis of circulating leukocytes by flow cytometry. An
additional 10 mL of blood was drawn into tubes without
anticoagulant to obtain serum used to quantify the levels
of circulating cytokines by cytometric beads array. Fine-
needle liver biopsies were collected from a subgroup of
Table 1 Study population
Characteristics Non-infected Controls (n = 28) HCV Patients (n = 18)
Age 40.3 ± 9.1 50 ± 8.9
Male/Female 20/8 10/08
Liver Fibrosis Score F1-2 NA 11
F3-4 NA 7
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HCV patient to obtain tissue specimens used for histo-
logical, immunophenotypic and cytokine analyses.
HCV viral load analysis
HCV genomic RNA test (HCV-RNA) was performed in the
Amplicor RT-PCR (Roche, NJ, USA), that presents a sensi-
tivity of 50 IU/mL. Samples with detectable HCV-RNA
were further genotyped throughout in-house RT-nested
PCR and RFLP analysis [13, 14] and viral load determined
by RT-PCR (Amplicor HCV Monitor, Roche, NJ, USA) with
data expressed as IU/mL.
Serum Alanine Transaminase (ALT) measurement
ALT activity was determined in serum samples collected
by venous puncture by using the ALT test (Abbott La-
boratories, Chicago, IL) and data was reported as inter-
national units (IU)/L.
Histological analysis
Fine needle liver biopsies were processed by the Central
Pathology Laboratory at FMT-HVD. Sections (4–5 μm)
of formalin-fixed and paraffin-embedded liver specimen
were stained with hematoxylin-eosin, reticulin and tri-
chrome dyes. The METAVIR score was used to classify
the liver fibrosis as either F1-2 or F3-4.
Preparation of intrahepatic leukocytes and tissue
homogenates
Fine needle biopsies were homogenized in tissue grinder
to obtain single cell suspension and tissue homogenate for
soluble cytokine analysis. Briefly, one section of the fine
needle biopsy was immersed in 1 mL of RPMI and macer-
ated using a pestle. The cell suspension was centrifuged to
obtain the supernatant used for tissue cytokine quantifica-
tion. The pellet was resuspended in phosphate-buffered
saline (PBS) supplemented with 5 % bovine serum albu-
min and used for immunophenotypic analysis.
Immunophenotypic analysis of whole blood leukocytes
An aliquot of 100 μL of EDTA whole blood or 50 μL of
tissue cell suspension was incubated in the presence
fluorescent labeled anti-human cell surface monoclonal
antibodies (anti-CD3-PerCP/CloneSK7, anti-CD4-PE/Clone
RPA-T4, anti-CD8-FITC/CloneHIT8a, anti-CD25-APC/
CloneM-A251, anti-FoxP3-PE/Clone259D/C7, all pur-
chased from BD Bioscience, San Diego, CA, USA) to
identify helper and cytotoxic T-cell subsets and Tregs.
Following incubation, cells were treated with 1 mL of
erythrocyte lysing solution for 10 min at room temperature.
After one wash step with PBS, cells were fixed in MFF fix
solution (10 g/L of paraformaldehyde, 10,2 g/L of sodium
cacodilate and 6.63 g/L of sodium chloride, pH7.2). Stained
cells were stored at 4 °C up to 24 h prior flow cytometric
acquisition. A total of 10,000/100,000 events were acquired
for each blood or tissue samples to quantify T-cell subsets
and Tregs, respectively. A dual laser FACScalibur flow cyt-
ometer (488 nm and 633 nm) was used for data acquisition
and storage as FCS files. The FlowJo software (TreeStar
Inc., Ashland, OR, USA) was used for data analysis. The
results were expressed as percentage of positive cells within
the lymphocyte gate.
Cytokine analysis
The serum cytokines quantification (IL-6, TNF, IL-2, IFN-
γ, IL-4, IL-10 and IL-17) was performed by Cytometric
Bead Array (CBA kit, BD Biosciences Pharmingen, USA)
according to the manufacturer’s specifications. A dual
laser FACScalibur flow cytometer (488 nm and 633 nm)
was used for data acquisition and storage as FCS files. The
FCAP array software was used for data analysis using the
fourth logistic parameter regression to calculate the re-
sults. Data was expressed as mean fluorescence intensity
(MIF) for each serum or tissue cytokine.
Data mining and statistical analysis
Conventional statistics
Comparative analysis between groups were performed to
evaluate the frequency of peripheral blood or tissue T-cell
subsets and Tregs as well as the tissue or serum cytokines
between groups, using the GraphPad Prism software, ver-
sion 5.0 (San Diego, CA, USA) using the nonparametric
Mann-Whitney test. Significance were considered in all
cases at P < 0.05.
Serum cytokine signature analysis
The serum cytokine signature analysis was carried out ac-
cording to Luiza-Silva et al. [15]. This innovative model
was designed to convert quantitative cytokine measure-
ments in a categorical analysis of low and high cytokine
producers. Briefly, the frequency of subjects with “High”
serum cytokine levels were determined taking the global
median value of serum cytokine levels obtained from the
whole data set (HCV patients +NI Controls) as described
[15]. The following values were used as the cut-off to segre-
gate low and high cytokine producers (IL-6 = 137.3; TNF =
81.5, IL-2 = 121.5; IFN-γ = 56.5; IL-4 = 129.4; IL-10 = 95.1
and IL-17 = 60.1). Ascendant tissue cytokine signatures
were assembled for each clinical group. The differences of
cytokine signatures between groups were addressed by
overlaid cytokine hierarchical curves, considering as “rele-
vant” frequencies of high cytokine producers those groups
with frequencies above the 50th percentile.
Biomarkers networks assembling
Biomarker networks were assembled to assess the asso-
ciation amongst serum cytokines. The correlations were
significant when Spearman’s test resulted in a P < 0.05.
Significant correlations were compiled using the open-
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access software Cytoscape (version 3.1.1), as previously
reported [16, 17]. The biomarker networks were con-
structed using circular nodes for each cytokine includ-
ing proinflammatory IL-6, TNF, IL-2 and IFN-γ (black
circles), modulatory IL-10 axis (light gray circle) and
additional IL-4 and IL-17 axes (dark gray circles). Con-
necting edges represent correlation scores categorized
as positive strong (r ≥ 0.68; thick continuous line), posi-
tive moderate (0.36 ≥ r ≤ 0.67; thin continuous line),
negative strong (r ≤ −0.68; thick dashed line), negative
moderate (−0.36 ≥ r ≤ −0.67; thin dashed line) as pro-
posed by Taylor [18].
Heatmaps analysis
The heatmaps were produced using the heatmap.2 func-
tion in the R (Project for Statistical Computing Version
3.0.1) and gplots package. Decision trees to select the
minimal set of immunological features that efficiently
segregated groups were built using the WEKA software
(Waikato Environment for Knowledge Analysis, version
3.6.11, University of Waikato, New Zealand). The classi-
fication accuracy of the decision trees when applied to
new data sets with unknown class labels was further
evaluated by a 10-fold cross validation methodology
available in the WEKA software.
Results
HCV patients with severe liver fibrosis (F3-4) presented
higher viral load as compared to those with mild fibrosis
Aiming to characterize the virological and liver damage
status in HCV patients according to the fibrosis score,
we have evaluated the viral load and the ALT levels
serum levels which are presented in Fig. 1. Data analysis
demonstrated that HCV patients with severe liver fibro-
sis (F3-4) presented higher viral load as compared to
those with mild fibrosis (Fig. 1). The ALT data revealed
that HCV patients presented high levels of this liver
damage biomarker but no significant differences be-
tween patients with mild or severe liver fibrosis were ob-
served (Fig. 1).
HCV patients display high frequency of CD8+ T-cells and
Tregs along with a mixed proinflammatory/IL-10-modulated
cytokine pattern
In an attempt to determine whether peripheral blood im-
munological biomarkers in HCV patients associate to the
liver fibrosis score, we have evaluated the frequency of
major T-cell phenotypes that are presented in Fig. 2. Data
analysis demonstrated that HCV patients display high fre-
quency of CD8+ T-cells and Tregs (Fig. 2a) along with a
mixed proinflammatory cytokine pattern (IL-6, TNF, IL-2,
IFN-γ), modulated by IL-10 along with a prominent IL-4
and IL-17 production as compared to non-infected con-
trols (Fig. 2b). No differences were observed neither in the
frequency of CD4+ T-cells nor in the CD4+/CD8+ T-cell
ratio (Fig. 2a).
HCV patients with severe liver fibrosis (F3-4) show lower
frequency of circulating CD8+ T-cells besides higher levels
of proinflammatory cytokines and lower levels of IL-10
Further analysis of peripheral blood biomarkers includ-
ing the quantitation of serum levels of proinflammatory
and regulatory cytokines in HCV patients according to
the fibrosis score are presented in Fig. 2. The results
demonstrated that HCV patients with moderate fibrosis
(F1-2) presented high frequency of CD8+ T-cells (Fig. 2a)
along with lower levels of proinflammatory cytokines
(IL-6 and IFN-γ) but higher IL-10 levels as compared to
those patients with severe liver fibrosis (F3-4) (Fig. 2b).
ALT Serum Levels































Fig. 1 Virological and liver damage (ALT) assessment in HCV patients according to the fibrosis score. a HCV viral load and (b) serum levels of
alanine aminotransferase (ALT) were determined in serum HCV patients ( ) categorized into subgroups referred as F1-2 ( ) and F3-4
( ) and compared to uninfected controls ( ). The results are expressed as mean ± SE viral copies/mL and mean ± SE IU/L, respectively.
Significant differences at P < 0.05 between HCV versus NI or F1-2 versus F3-4 are highlighted by connecting lines. Differences between HCV
subgroups (F1-2 or F3-4) in comparison to NI are highlighted by “*”. NA = Non Applicable
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Despite the lower frequency of intrahepatic CD4+, CD8+
T-cells, HCV patients with severe liver fibrosis (F3-4) have
higher levels of proinflammatory cytokines (TNF and IFN-γ)
and the presence of scarce frequency of Tregs as compared
to those with mild liver disease (F1-2)
Aiming to validate whether the observed pattern of per-
ipheral blood biomarkers (Figs. 1 and 2) reflect the overall
hepatic tissue immunological milieu, we have assessed the
tissue cell phenotypes and tissue cytokine levels in HCV
patients according to their liver fibrosis by flow cytometry,
which are presented in Fig. 3. Data analysis demonstrated
that although HCV patients with severe fibrosis (F3-4)
presented low frequency of intrahepatic CD4+, CD8+ T-
cells (Fig. 3a), they present higher tissue levels of proin-
flammatory cytokines (TNF and IFN-γ) along with low
frequency of Tregs as compared to patients with mild liver
fibrosis (F1-2) (Fig. 3a and b). Taken together, these data
demonstrates that regardless the divergences in the fre-
quency of intrahepatic T-cells, HCV patients have com-
parable tissue levels of proinflammatory cytokines (TNF
and IFN-γ) according to their liver fibrosis score. The
similarities between tissue and peripheral blood cytokine
patterns supported the further use of serum cytokines as
putative biomarkers associated to the liver fibrosis score.
Cytokine signature analysis further highlight that HCV
patients with mild liver fibrosis (F1-2) presented higher
IL-10 serum levels as compared to those with severe liver
disease (F3-4)
The analysis of cytokine signatures in HCV patients
categorized according to their liver fibrosis score are
shown in Fig. 4. Our data demonstrated that HCV
CD4+ T-cells


















































































































































Fig. 2 Peripheral Blood Biomarkers in HCV patients according to the fibrosis score. a Frequency of circulating T-cell subsets (CD4+, CD8+, Treg
and CD4+/CD8+ ratio) in HCV patients ( ) categorized into subgroups referred as F1-2 ( ) and F3-4 ( ) as compared to uninfected
controls ( ). b Levels of serum cytokines (IL-6, TNF, IL-2, IFN-γ, IL-4, IL-10 and IL-17). Data are expressed as mean ± standard deviation for the
percentage of gated lymphocytes for circulating T-cell subsets or serum concentration (MFI) for cytokines. Statistical analyses were performed by
the Mann–Whitney test for comparisons between groups. Significant differences at P < 0.05 between HCV versus NI or F1-2 versus F3-4 are represented
by connecting lines. Differences between HCV subgroups (F1-2 or F3-4) in comparison to NI are highlighted by “*”
de Souza-Cruz et al. BMC Microbiology  (2016) 16:3 Page 5 of 12
patients presented a cytokine storm characterized by
relevant frequency of high serum cytokine producers
as compared to non-infected controls (Fig. 4a). The
analysis of cytokine signatures further underscored
that the subgroup of patients with mild liver fibrosis
(F1-2) presented relevant frequency of subjects with
high IL-10 serum levels as compared to patients with












































































































































Fig. 3 Hepatic Tissue Biomarkers in HCV patients according to the fibrosis score. a Frequency of intrahepatic T-cell subsets (CD4+, CD8+, Treg and
CD4+/CD8+ ratio) in HCV patients ( ) categorized into subgroups referred as F1-2 ( ) and F3-4 ( ). b Levels of tissue cytokines (IL-6, TNF, IL-2,
IFN-γ, IL-4, IL-10 and IL-17) secreted by mononuclear cells cultured in vitro for 12 h in RPMI (1x106cells/mL) at 37 °C, 5 % CO2. Data are expressed
as scattering of individual percentage of intra-hepatic T-cell subsets within gated lymphocytes or tissue for cytokine concentration (MFI). The median
values of each biomarker was calculated for the HCV group and used as a cut off to segregate subjects presenting high (continuous lined rectangle) or
low (dashed lined rectangle) biomarker levels. The Chi-square test was used to compare the frequency of subjects presenting high or low biomarker
levels between the HCV subgroups (F1-2 versus F3-4). The frequencies of subjects presenting high or low biomarker levels in the F1-2 versus F3-4
subgroups are provided in the figure. In all cases, significant differences at P < 0.05 were found between F1-2 versus F3-4



























































































































































































































































































B Cytokine Signature in HCV Subgroups
Ascendant cytokine signature
Ascendant cytokine signature
Fig. 4 (See legend on next page.)
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There is a clear positive connection of IL-10 controlling
the TNF node in HCV patients with mild liver fibrosis (F1-2),
whereas an evident negative axes of IL-10 with all other
cytokine nodes highlights the absence of modulatory
events in HCV patients with severe liver fibrosis (F3-4)
Data analysis demonstrate that HCV patients presented
a more imbricate cytokine network amongst proinflam-
matory cytokines (continuous axes) counterbalanced by
inverse relationship with IL-10 (dashed axes) and direct
correlation between IL-4 and IL-17 axes (Fig. 5a). Re-
gardless the liver fibrosis score, this direct correlation
between IL-4 and IL-17 axes is preserved (Fig. 5b). HCV
patients with mild liver fibrosis (F1-2) showed stronger
connections between proinflammatory cytokines with a
clear positive connection of IL-10 controlling the TNF
node. On the other hand, HCV patients with severe liver
fibrosis (F3-4) displayed significant inverse correlation
between IL-10 and all other cytokines (Fig. 5b).
Machine learning data mining pointed out TNF and IL-10 as
the major attributes to identify HCV patients in comparison
to non-infected individuals with outstanding performance
Computational bioinformatics analysis of serum cytokine
levels in HCV patients clearly demonstrated the ability
of these attributes to cluster HCV patients, with up-
regulated levels apart from the basal levels observed in
(See figure on previous page.)
Fig. 4 “Cytokine signatures” in HCV patients according to the fibrosis score. The ascendant frequency of subjects with “high” serum cytokine
levels was assembled for (a) HCV patients ( ) and uninfected controls ( ) as well as (b) for the HCV patients categorized into subgroups
referred as F1-2 ( ) and F3-4 ( ). Relevant elements in the cytokine signature that emerge above the 50th percentile (cut-off line) were
highlighted by *. Additional analyses were carried out to identify relevant elements in the cytokine signature able to differentiate clinical groups (HCV
versus NI or F1-2 versus and F3-4) and the elements in the cytokine signature of each group that emerge above the 50th percentile were highlight by
grayscale background rectangles
NI HCV





















Fig. 5 “Cytokine Networks” in HCV patients according to the fibrosis score. Customized biomarker network layouts were built to identify the
relevant association between proinflammatory IL-6, TNF, IL-2 and IFN-γ cytokines (black circles), modulatory IL-10 axis (light gray circle) and additional IL-4
and IL-17 axes (dark gray circles), using a clustered distribution of nodes. Significant Spearmam’s correlations at P< 0.05 were represented by connecting
edges to highlight positive [strong (r≥ 0.68; thick continuous line) or moderate (0.36≥ r≤ 0.67; thin continuous line)] and negative [strong (r≤−0.68; thick
dashed line) or moderate (−0.36≥ r≤−0.67; thin dashed line)] as proposed by Taylor [18]. The overall statistic analysis of the network node neighborhood
connections point out for an almost linear-chain pattern in the NI groups with a clear shift towards a more imbricate profile in HCV patients. A persistent
IL17/IL-4 loop was observed in all HCV subgroups with differential neighborhood connections for the IL-10 node in HCV patients according to the
fibrosis score
de Souza-Cruz et al. BMC Microbiology  (2016) 16:3 Page 8 of 12
non-infected individuals (Fig. 6a). On the other hand,
the heatmap analysis does not show the same perform-
ance to segregate the HCV patients according to their
liver fibrosis scores (Fig. 6b). The decision trees further
revealed that TNF and IL-10 are the major attributes
able to categorize HCV patients aside from non-infected
individuals with a global accuracy of 100 %, reaching
86 %, after leave-one-out cross validation (Fig. 6c). Trel-
lis scatter plot for serum cytokine analysis reinforce the
outstanding ability of the selected attributes to segregate
the HCV patients from non-infected individuals, point-
ing out the relevant cytokine storm associated with
HCV infection (Additional file 1: Figure S1). In contrast,
the decision trees generated to cluster HCV patients ac-
cording to their liver fibrosis score showed a global ac-
curacy of 88.9 %, reaching 77.8 %, after leave-one-out
cross validation (Fig. 6d).
Discussion
HCV infection is a severe liver disease that constitutes
a major health problem associated with high rates of
morbidity and mortality due to recurrent complications,
such as fibrosis progression, liver cirrhosis and hepatocel-
lular carcinoma [5, 6]. The immune response against
HCV infection has a pivotal but dual role during the
course of infection. The early immunological events trig-
gered by the virus have the potential to contribute to viral
elimination and induce protective immunity, however, as
the disease progresses; the late immunological events
during the chronic phase may lead to liver damage [7].
The role of proinflammatory response is well discussed
in the chronic phase of HCV infection and several stud-
ies have shown the importance of cytokines such as IL-
1β, TNF, IFN-γ, IL-2, IL-6 and IL-12 during the course
of HCV infection. It was reported variations in serum
cytokine levels such as an increase in IFN-γ and IL-2,
IL-4 and the regulatory IL-10 in the serum from patients
with HCV infection as compared to the control group
[19, 20]. Other studies reported a decrease of IL-4 [21],
while Zhang et al. [22] reported a decrease in IL-2 serum
levels of HCV patients. Previous data from our group
have demonstrated the importance of TNF in HCV in-
fection and treatment along with other proinflammatory
cytokines such as IL-12, IFN-γ, IL-6, as well as the
regulatory cytokines such as IL-4 and IL-10 [23].
Regarding the regulatory cytokines, studies demon-
strated that the serum levels of IL-4 and IL-10 were sig-
nificantly increased in the control group than the patients
[24–26]. However, Sofian et al. [27] demonstrated that,
both the concentration of the proinflammatory IL-2 and
IFN-γ as well as the regulatory IL-4 and IL-10 are in-
creased in serum of HCV patients as compared to the
control group. In the analysis of serum cytokines in HCV
patients, however, no significant differences were found in
relation to the progression fibrosis between the groups ≤
F2 and ≥ F3. The stringency in categorizing patients ac-
cording to their fibrosis score may vary, which may lead to
divergence in results.
However, analyzing the individuals into “high” and “low”
producers of cytokines in serum of control group, moder-
ate fibrosis ≤ F2 and severe fibrosis ≥ F3 group showed
that there is no high cytokine producers in the control
group, while in the group of moderate fibrosis (≤F2) there
is an elevated frequency of high cytokine producers with
particularly high concentrations of IL-4, followed by TNF-
α, IL-2, IL-6, IL-17, IFN-γ and IL-10. These data suggest
an important role of IL-4 in controlling the development
of hepatic lesions in the group of moderated fibrosis,
whereas IL-2 could contribute to the development of se-
vere fibrosis. The development of regulatory response is
supported by IL-4, which antagonizes the production of
IFN-γ and IL-2 promotes the development of a robust
proinflammatory profile, which antagonizes the develop-
ment of a regulatory environment [28]. Studies showed
than the exchange of cytokines has been associated with
increased activity necrosis followed by inflammation dur-
ing liver fibrosis [29, 30].
The group of severe fibrosis ≥ F3 demonstrated a high
percentage of individuals with particularly high concentra-
tions of IL-2, followed by TNF-α, IL-4, IL-6, IL-17, IFN-γ.
An interesting finding was that in the group with severe
fibrosis ≥ F3, there is no relevant percentage of IL-10 high
producers, which highly suggests that this cytokine may
be involved in the control of inflammation-induced fibro-
sis formation. IL-10 is a regulatory cytokine that negatively
regulates the expression of MHC-II and co-stimulatory
molecules on antigen presenting cells, and inhibits T-cell
activation via co-molecule stimulatory CD28 inhibition
[31, 32]. The persistently elevated levels of IL-10 during
HCV infection supposedly produced by suppressing regu-
latory T-cells may be an attempt to control fibrosis, thus
contributing to the decline of the effector response against
viruses and, therefore, preventing lesion expansion medi-
ated by excessive cytotoxicity [33, 34, 35]. On the other
hand, the low production of this cytokine may result in
increased inflammatory responses and consequently
excessive aggression to liver tissue.
Aroucha et al. [36] indicate a protective role of IL-10
in patients with moderate fibrosis, reinforcing our
hypothesis that IL-10 plays a protective role in HCV in-
fection regarding the progression of hepatic fibrosis.
Other studies have emphasized the protective role of
IL-10 used in the treatment of chronic hepatitis c infec-
tion, which had decreased severity of fibrosis in en-
rolled individuals [37]. In other studies with animal
models, it was demonstrated that the absence of IL-10
was associated with liver fibrosis [38, 39]. In contrast to
these data in a study by Abayli et al. [25] using IL-10
de Souza-Cruz et al. BMC Microbiology  (2016) 16:3 Page 9 of 12




















































































































































































































































































































Fig. 6 Computational bioinformatics analysis of serum cytokine levels in HCV patients according to the fibrosis score. Machine learning data
mining was represented by heatmaps (a and b) and decision-trees (c and d) of z-score-normalized events. The heatmap computational method
was applied to pre-process the serum cytokine data, in addition to identifying the attributes matching those across samples and clusters of
individuals. a Serum cytokine attributes showed clear ability to cluster HCV patients, with up-regulated levels, apart from non-infected individuals,
with basal levels of serum cytokines. b Heatmap analysis showed low performance to segregate the HCV patients according to their liver fibrosis
scores. c Decision tree analysis provided the identification of “root” (TNF) and “secondary” (IL-10) attributes with high accuracy to categorize HCV
patients aside from non-infected individuals. d Decision tree analysis showed moderate global performance of “root” (IFN-γ) and “secondary”
(TNF) attributes to cluster HCV patients according to their liver fibrosis score
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and histological activity, there was no correlation be-
tween these parameters.
In summary, the cytokine signature shows absence of
high producers among HCV patients with moderate fi-
brosis (≤F2), which were characterized mainly by an in-
crease of IL-4 and IL-10, while patients with severe
fibrosis (≥F3) were characterized mainly by an increased
IL-2 and decreased IL-10, reinforcing our hypothesis of
the protective effect of the regulatory cytokines specially
IL-10 in these subjects, as previously mentioned.
The activity of proinflammatory and regulatory cyto-
kines is a dynamic event that will influence the progres-
sion of liver injury, contributing to reducing the damage
caused by the virus or regulating the excessive response
of effector cells. The knowledge about the mechanisms
that control the production and secretion of such cyto-
kines during the progression of liver fibrosis may con-
tribute to the identification of potential therapeutic
biomarkers to assess disease progression and alleviate
the complications related to HCV infection.
Conclusion
In conclusion, our findings demonstrated that HCV in-
fection triggers a local and systemic cytokine ensemble
orchestrated by TNF and tuned by IL-10 in such a man-
ner that mirrors the liver fibrosis score, which highly
suggests the relevance of these set of biomarkers for
clinical investigations.
Additional file
Additional file 1: Figure S1. Trellis scatter plot for serum cytokine
analysis in HCV patients and non-infected controls. Scatter plot matrix
analysis pointed out the relevant cytokine storm associated with HCV
infection and reinforce the outstanding ability of serum cytokine attri-
butes to cluster the HCV patients apart from non-infected individuals.
(PPTX 2359 kb)
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